MAPT and Alzheimer disease: The current study demonstrates, for the first time, that the prenatal administration of BM-MSCs and GSI-953 can prevent not only cognitive deficiency but also pathological alterations typical of AD, such as tau pathologies and neuroinflammation later in infants.